NEW YORK (GenomeWeb) – Genome mapping company BioNano Genomics said in a regulatory filing that it raised $5 million toward a targeted $6.1 million financing round.

In a document filed with the US Securities and Exchange Commission last week, BioNano said that the type of securities offered included debt; option, warrant, or other rights to acquire another security; and security to be acquired upon the exercise of an option, warrant, or other right to acquire security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.